TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 8595636
Drug: Cefuroxime axetil
Normalized name: Cefuroxime Axetil
DrugBank: Cefuroxime (DB01112)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefuroxime axetil suspension
Study: 2113874
Drug: Amoxycillin syrup
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amoxycillin syrup
Study: 460026
Drug: Etozolin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etozolin (800 mg p.o.)
Study: 460026
Drug: Furosemide (80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (80 mg p.o.)
Study: 460026
Drug: Etozolin (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etozolin (800 mg p.o.) and Furosemide (80 mg p.o.)
Study: 22917075
Drug: Enriched cheese
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enriched cheese (90 g/d for 3 weeks)
Study: 22917075
Drug: Control cheese
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control cheese (90 g/d for 3 weeks)
Study: 20802006
Drug: Cisplatin 80
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin 80 mg/m(2) on days 1 and 29, Irinotecan 60 mg/m(2) on days 1, 8, 15, 29, 36, and 43, and 30 mg/m(2) on days 57, 64, 71, 78, 85 and 92, followed by thoracic radiotherapy starting on day 57 at 2 Gy/day (total 60 Gy)
Study: 9394979
Drug: Topically applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Topically applied PAF antagonist (RO‐24‐0238)
Study: 27762662
Drug: Caffeine (1.5‐3.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine (1.5‐3.0 mg · kg‐1 day‐1; titrated)
Study: 18279051
Drug: Zinc lozenges
Normalized name: Zinc Lozenges
DrugBank: Zinc gluconate (DB11248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Zinc lozenges (13.3 mg of zinc as zinc acetate)
Study: 15689918
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone (T) + letrozole (Lz; 2.5 mg/d)
Study: 15689918
Drug: Low-dose testosterone
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose testosterone (T) + placebo (P)
Study: 10501791
Drug: Clodronate 400
Normalized name: clodronic acid 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate 400 mg daily
Study: 1985428
Drug: Dietary control
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary control of blood phenylalanine below 900 mumol/L maintained beyond age 10 years
Study: 1985428
Drug: Dietary control
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary control not maintained (blood phenylalanine persistently above 900 mumol/L)
Study: 16350383
Drug: Hyaluronan-based heparin-bonded
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyaluronan-based heparin-bonded circuits
Study: 12115160
Drug: Psychological interventions
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Psychological interventions (e.g., relaxation, biofeedback, cognitive‐behavioral therapy)
Study: 9857535
Drug: Dexamethasone (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (250 mg), Promethazine (300 mg), Dextran 70 (500 ml intraperitoneally)
Study: 8589875
Drug: Left-sided approach
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left-sided approach with submuscular or subcutaneous patch
Study: 8589875
Drug: Right-sided approach
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-sided approach with submuscular or subcutaneous patch
Study: 8589875
Drug: Left-sided approach
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left-sided approach without submuscular or subcutaneous patch
Study: 8589875
Drug: Right-sided approach
Normalized name: cured fat, pork side bacon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Right-sided approach without submuscular or subcutaneous patch
Study: 31302000
Drug: Aspiration Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspiration Therapy (AT) plus Lifestyle Therapy
Study: 31302000
Drug: Lifestyle Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lifestyle Therapy
Study: 29085538
Drug: Heated gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heated gel (102.0° F)
Study: 29085538
Drug: Room-temperature gel
Normalized name: ROOM DEODORIZER POWDER MENTOR #3202
Approvals — FDA: no, EMA: no, PMDA: no
Description: Room-temperature gel (82.3° F)
Study: 21762229
Drug: Budesonide (BUD)
Normalized name: Budesonide
DrugBank: Budesonide (DB01222)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Budesonide (BUD) 2 mg inhalation suspension
Study: 8956674
Drug: Clozapine (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (mean final dose 176 ± 149 mg/d)
Study: 8956674
Drug: Haloperidol (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haloperidol (mean final dose 16 ± 8 mg/d)
Study: 1285568
Drug: L-648,051 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 (6 mg, four times daily for 7 days)
Study: 1285568
Drug: L-648,051 (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-648,051 (6 mg, inhaled before antigen challenge)
Study: 22849787
Drug: Automated text
Approvals — FDA: no, EMA: no, PMDA: no
Description: Automated text messaging (SMS) system providing daily queries about prescription pickup and dosage taken with educational feedback
Study: 18197974
Drug: Lactobacilli treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli treatment (109 freeze-dried lactobacilli for 10 days during 3 menstrual cycles)
Study: 18197974
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (identical placebo capsules for 10 days during 3 menstrual cycles)
Study: 18197974
Drug: Lactobacilli treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacilli treatment
Study: 9216851
Drug: PVB chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB chemotherapy (cisplatin, vinblastine, bleomycin)
Study: 9216851
Drug: CAP chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAP chemotherapy (cyclophosphamide, aclacinomycin, cisplatin)
Study: 9216851
Drug: PVB chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: PVB chemotherapy
Study: 27788313
Drug: Control Therapy
Normalized name: Benzoyl Peroxide;Salicylic Acid;Vitamin E 8%; 2%; 5% Topical application Kit [INOVA 8/2 ACNE CONTROL THERAPY]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control Therapy for Insomnia (CTRL)
Study: 24999158
Drug: Community Health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Community Health Workers (CHW's) intervention with monthly visits
Study: 16642920
Drug: Prostaglandin E1
Normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prostaglandin E1 (PGE1) administered at 20 ng/kg/min from just after the induction of anesthesia to the end of surgery
Study: 16642920
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no PGE1 treatment)
Study: 14714362
Drug: Integrative Chinese
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative Chinese and Western Medicine (ICWM)
Study: 10323118
Drug: Oral midazolam
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral midazolam (0.6 mg/kg)
Study: 4008807
Drug: Chlorpheniramine (24
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (24 mg per day)
Study: 4008807
Drug: Chlorpheniramine (doubled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlorpheniramine (doubled dose from days 22 to 24)
Study: 25129967
Drug: Self-treatment combined
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment combined with modified Epley maneuver
Study: 25129967
Drug: Hand repositioning
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hand repositioning in self-treatment group
Study: 25129967
Drug: Chair-assisted repositioning
Normalized name: Medium-Chain Triglycerides
DrugBank: Medium-chain triglycerides (DB13959)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chair-assisted repositioning in self-treatment group
Study: 25129967
Drug: Self-treatment group
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-treatment group
Study: 19889241
Drug: Caffeinated coffee
Normalized name: Coffee bean
DrugBank: Coffee bean (DB10525)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeinated coffee (CC) (5 mg caffeine/kg body weight)
Study: 18620591
Drug: Ringer solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Study: 18620591
Drug: HES 130‐0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130‐0.4 solution (1500 ml + 200 ml mannitol + 60 ml sodium bicarbonate + 150 U/kg heparin)
Study: 12462286
Drug: Olopatadine 0.1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olopatadine 0.1% ophthalmic solution BID
Study: 12462286
Drug: Cromolyn 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cromolyn 2% ophthalmic solution QID
Study: 10730526
Drug: Gentamicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.5 mg/kg/d once daily (OD group)
Study: 10730526
Drug: Gentamicin 4.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin 4.5 mg/kg/d in three divided doses (TID group)
Study: 7670450
Drug: High Carbohydrate
Normalized name: High carbohydrate food
Approvals — FDA: no, EMA: no, PMDA: no
Description: High Carbohydrate Diet (HCD) - 4.5 +/‐ 0.5 g CHO.kg‐1.d‐1 for 3 days followed by 8.2 +/‐ 0.4 g CHO.kg‐1.d‐1 for 3 days
Study: 7670450
Drug: Mixed Diet
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed Diet (MD) - 4.0 +/‐ 0.5 g.kg‐1.d‐1 of carbohydrate for 6 days
Study: 7389388
Drug: Cefaclor 250
Normalized name: cefaclor 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefaclor 250 mg 8-hourly
Study: 7389388
Drug: Ampicillin 250
Normalized name: ampicillin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ampicillin 250 mg 6-hourly
Study: 31841363
Drug: Standard-Dose Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-Dose Radiation (60 Gy) with concurrent chemotherapy
Study: 31841363
Drug: High-Dose Radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Dose Radiation (74 Gy) with concurrent chemotherapy
Study: 27348462
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy via computer teleconferencing
Study: 27348462
Drug: Prolonged exposure
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged exposure (PE) therapy via iPhone
Study: 18057480
Drug: Cefpodoxime Proxetil
Normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefpodoxime Proxetil (CP) 16 mg/kg/day
Study: 18057480
Drug: Cefixime (CF)
Normalized name: Cefixime
DrugBank: Cefixime (DB00671)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cefixime (CF) 20 mg/kg/day
Study: 11006365
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a (30 microg weekly intramuscular injections)
Study: 11006365
Drug: Placebo (weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (weekly injections)
Study: 8875379
Drug: Dried garlic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dried garlic tablets (standardised to 1.3% allicin) at a dosage of 300 mg three times daily
Study: 2049420
Drug: Vancomycin 25
Normalized name: vancomycin 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vancomycin 25 mgm/L
Study: 2049420
Drug: Cefazolin 50
Normalized name: cefazolin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefazolin 50 mgm/L
Study: 6839757
Drug: Oestrogen-progestogen combination
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oestrogen-progestogen combination
Study: 30499227
Drug: Group Cognitive
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Cognitive Behavioral Treatment (GCBT)
Study: 30499227
Drug: Group Present-Centered
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group Present-Centered Treatment (GPCT)
Study: 19143690
Drug: Tramadol 1
Normalized name: tramadol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tramadol 1 mg.kg(‐1)
Study: 22927775
Drug: Propofol-lidocaine mixture
Normalized name: brown mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol-lidocaine mixture (20 mg lidocaine with 180 mg 1% propofol)
Study: 15118486
Drug: Donepezil (acetylcholinesterase
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (acetylcholinesterase inhibitor)
Study: 11777514
Drug: Propofol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 0.5 mg/kg per hour
Study: 11777514
Drug: Propofol 1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.0 mg/kg per hour
Study: 11777514
Drug: Propofol 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2.0 mg/kg per hour
Study: 7627338
Drug: Intramuscular hMG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular hMG at a daily dose of 150 IU in combination with buserelin
Study: 7627338
Drug: Pulsatile intravenous
Normalized name: PULSATILLA PRATENSIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsatile intravenous hMG at a daily dose of 112.5 IU in combination with buserelin
Study: 2039326
Drug: One-dose cefazolin
Normalized name: Next Choice One Dose
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: One-dose cefazolin
Study: 2039326
Drug: Six-dose cefazolin
Normalized name: Cefazolin
DrugBank: Cefazolin (DB01327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Six-dose cefazolin
Study: 20127230
Drug: Oral cladribine
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral cladribine
Study: 12377315
Drug: High-dose fractionated
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose fractionated preoperative radiotherapy (5 x 5 Gy)
Study: 11122794
Drug: Dose-intensive chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-intensive chemotherapy
Study: 11122794
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose therapy
Study: 7572019
Drug: Polygeline 35
Normalized name: polygeline 35 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polygeline 35 mg.ml‐1 (Haemaccel)
Study: 7572019
Drug: Dextran 70
Normalized name: Dextran 70
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextran 70 (Macrodex) 60 mg.ml‐1
Study: 7572019
Drug: Albumin 40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Albumin 40 mg.ml‐1 in saline
Study: 7000227
Drug: Prophylactic metronidazole
Normalized name: Metronidazole
DrugBank: Metronidazole (DB00916)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylactic metronidazole (1-g suppository with premedication and 200 mg t.d.s. orally for 7 days)
Study: 28087506
Drug: Ustekinumab 90
Normalized name: ustekinumab 90 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ustekinumab 90 mg at weeks 0, 4 and every 8 weeks
Study: 28087506
Drug: Guselkumab 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 50 mg at weeks 0, 4 and every 8 weeks
Study: 28087506
Drug: Guselkumab 200
Normalized name: guselkumab 200 MG in 20 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guselkumab 200 mg at weeks 0, 4 and every 8 weeks
Study: 21161742
Drug: Intraarticular injection
Normalized name: dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intraarticular injection of an IL‐1 inhibitor
Study: 19067085
Drug: Culturally tailored
Normalized name: casein, emmental cultured
Approvals — FDA: no, EMA: no, PMDA: no
Description: Culturally tailored navigator program including educational material, phone or in-person contact by language-concordant navigators, patient education, procedure scheduling, translation of bowel preparation, and assistance with transportation and insurance coverage.
Study: 15996033
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose H(2)RAs
Study: 15996033
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose proton pump inhibitors
Study: 15996033
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose other proton pump inhibitors
Study: 15996033
Drug: Standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dose omeprazole
Study: 1907907
Drug: Gabapentin 1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin 1,200 mg/day
Study: 7066137
Drug: Etomidate (0.1-0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.1-0.4 mg kg‐1)
Study: 7066137
Drug: Additional injections
Normalized name: chromous chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional injections of etomidate
Study: 7066137
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of etomidate
Study: 31838148
Drug: Moderate training
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate training group (MG)
Study: 30597719
Drug: Medtronic SCS
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic SCS device (primo-implant)
Study: 30597719
Drug: Medtronic SCS
Normalized name: SC 41930
DrugBank: SC 41930 (DB17101)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medtronic SCS device (replacement implant)
Study: 22775239
Drug: ABT-102 6
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-102 6 mg
Study: 22775239
Drug: ABT-102 2
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-102 2 mg
Study: 22775239
Drug: ABT-102 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-102 0.5 mg
Study: 15006580
Drug: Surgery and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgery and adjuvant chemotherapy (9 cycles of 5 days every 4 weeks; daily administration of 200 mg/m² folinic acid, 5-fluorouracil starting at 375 mg/m² increasing to 500 mg/m², and CDDP 15 mg/m²)
Study: 11732150
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A fortified biscuits with de-worming treatment
Study: 11732150
Drug: Vitamin A
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin A fortified biscuits without de-worming treatment
Study: 11732150
Drug: Antihelminthic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihelminthic treatment
Study: 9219700
Drug: Prednisone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone (0.5 to 0.8 mg/kg/day) and aspirin (100 mg/day)
Study: 9219700
Drug: Prednisone and
Normalized name: chloroprednisone and antiinfectives
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prednisone and aspirin
Study: 8195582
Drug: Amitriptyline 115
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amitriptyline 115 mg/day
Study: 8195582
Drug: Alprazolam 3.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam 3.2 mg/day
Study: 3591728
Drug: Zinc-histidine (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc-histidine (15 mg)
Study: 3591728
Drug: Zinc preparations
Normalized name: zinc preparations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc preparations (both zinc-histidine and zinc sulfate)
Study: 27665195
Drug: Hypofractionated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated treatment
Study: 27665195
Drug: Hypofractionated treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypofractionated treatment vs Conventional treatment
Study: 24964505
Drug: Oral vitamin
Normalized name: vitamin A Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral vitamin K antagonists (VKAs)
Study: 20026501
Drug: 6 weeks
Normalized name: perampanel
DrugBank: Perampanel (DB08883)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 weeks of abduction treatment
Study: 20026501
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (treatment and surveillance)
Study: 18164001
Drug: Monophasic oral
Normalized name: hyoscyamine / methenamine / methylene blue / phenyl salicylate / sodium phosphate, monobasic Oral Tablet [Urelle]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monophasic oral contraceptive pill (ethinylestradiol plus norethisterone)
Study: 1348168
Drug: 0 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg/70 kg dezocine
Study: 1348168
Drug: 2.5 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg/70 kg dezocine
Study: 1348168
Drug: 5.0 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5.0 mg/70 kg dezocine
Study: 1348168
Drug: 10 mg/70
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/70 kg dezocine
Study: 27126971
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day for 5 days, started the next day after finishing medroxyprogesterone acetate course (early induction)
Study: 27126971
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate (CC) 100 mg/day for 5 days, started on day 2 of withdrawal bleeding (late induction)
Study: 23038702
Drug: Curcumin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin (1 g/d, n = 46)
Study: 19301936
Drug: niacin extended-release
Normalized name: Niacin Extended-Release Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: niacin extended-release (NER) 500 mg/day in week 1, 1000 mg/day in week 2, and 2000 mg/day in weeks 3-6/aspirin (ASA)
Study: 17493057
Drug: Pre-treatment methamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment methamphetamine use
Study: 17493057
Drug: Gender, route
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gender, route of administration, and pre-treatment methamphetamine use
Study: 9722054
Drug: butorphanol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: butorphanol (2 mg) + bupivacaine (0.25%)
Study: 8051795
Drug: L-627 (biapenem)
Normalized name: L
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-627 (biapenem) 6 mg/kg